Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancer.

Breast Cancer Res Treat · 2025 · PMC12660444 · PMID 41307769

Europe PMC DOI

hedged sentence

0.0810

closest p · 1.6× alpha

0.0810

boldest claim

The sentences

a numerical trendp = 0.081so close (0.05 < p ≤ 0.1)

Lastly, patients with de novo MBC did not have significantly different outcomes compared to those with recurrent disease, although there was a numerical trend toward improved PFS in the de novo group ( p = 0.081, Supplementary Fig. 1B, Supplementary Table 6).

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.